Alzheimer's Disease: FDA greenlights first-of-its-kind blood test for Alzheimer's disease: How does it work?
The US Food and Drug Administration (FDA) has granted marketing clearance for a new blood test designed to assist in the diagnosis of Alzheimer's disease, marking it as the first test approved in the United States for the early detection of this condition.
Tired of too many ads? go ad free now
How does the blood test work?
Named the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio, this test is intended for adults aged 55 and older who exhibit signs and symptoms of Alzheimer's. The FDA announced this development on a Friday, highlighting the significance of the test that analyzes two specific proteins in blood plasma: pTau217 and beta-amyloid 1-42. The ratio of these proteins is known to correlate with the presence or absence of amyloid plaques in the brain, which are characteristic markers of Alzheimer's disease, although the test does not directly measure amyloid levels.
Currently, there is no singular test for diagnosing Alzheimer's disease. Physicians typically utilize a comprehensive approach that includes an evaluation of medical history, neurological exams, cognitive and functional assessments, brain imaging, spinal fluid analysis, and, more recently, blood tests. The results from this newly approved blood test will need to be interpreted alongside other clinical information pertaining to the patient.
FDA Commissioner Dr. Martin Makary emphasized the profound impact of Alzheimer's disease on the population, noting that it affects more individuals than breast and prostate cancer combined. He pointed out that approximately 10% of people aged 65 and older are living with Alzheimer's, a figure expected to double by 2050. Dr. Makary expressed optimism that innovative medical products, like this blood test, will significantly benefit patients.
Tired of too many ads? go ad free now
A new hope:
Developed by Fujirebio Diagnostics Inc., a biotechnology company based in Pennsylvania, the new blood test aims to improve access to Alzheimer's detection and lessen the reliance on positron emission tomography (PET) scans. PET scans can reveal the presence of amyloid plaques in the brain, but they are often costly, sometimes amounting to thousands of dollars without insurance coverage.
The FDA assessed clinical trial data involving plasma samples from 499 cognitively impaired adults.
The study compared the blood test results with findings from PET scans or cerebrospinal fluid analysis, such as results from spinal taps. According to the FDA, the data demonstrated that 91.7% of the adults with positive blood test outcomes had confirmed amyloid plaques via their PET scans or cerebrospinal fluid tests, while 97.3% of those with negative blood test results also had negative outcomes in their PET scans or cerebrospinal fluid tests.
The agency cautioned that the main risks associated with this blood test involve the potential for false-positive or false-negative results.
The new era:
A "new era" in Alzheimer's research is emerging, highlighted by recent advancements in diagnostic methods. Dr. Richard Isaacson, a preventive neurologist and pioneer in Alzheimer's prevention, has been utilizing an FDA-cleared blood test in his research for several years.
This test helps determine whether individuals experiencing memory loss may be suffering from Alzheimer's disease. According to Isaacson, this blood test serves as a simpler and more cost-effective alternative to traditional diagnostic methods, such as PET scans or spinal taps.
While the FDA's approval represents significant progress, Isaacson cautions that further research is essential to clarify how the results of this blood test should be interpreted and applied in clinical settings.
He emphasizes the need for enhanced education surrounding the implications of the test results, noting that their meaning can vary based on individual risk factors and symptoms.
Fujirebio Diagnostics developed this blood test to facilitate early detection of Alzheimer's disease, which is crucial for timely intervention. Monte Wiltse, the company's president and CEO, stated that accurate, early diagnosis could drive the creation of new drug therapies, especially given the increasing prevalence of Alzheimer's disease associated with global population aging.
Statistics indicate that over 40% of individuals aged 55 and older in the United States are expected to develop dementia in their later years. Importantly, amyloid deposits may accumulate in the brain years before symptoms appear, suggesting that early detection could enable proactive measures to slow the disease's progression, including preventive treatments.
Dr. Maria Carrillo, chief science officer at the Alzheimer's Association, expressed optimism that this recent
will make accurate diagnoses more accessible.
Although several lab-developed tests exist to identify blood-based biomarkers linked to Alzheimer's, the Fujirebio test is the first to gain FDA clearance, marking a milestone in the field.
Carrillo noted that blood-based biomarkers are transforming our understanding and identification of Alzheimer's disease. However, there remain critical considerations for healthcare professionals regarding who should be tested and when.
Dr. Howard Fillit, co-founder of the Alzheimer's Drug Discovery Foundation, remarked on the significance of being able to diagnose Alzheimer's more readily with a simple blood test—comparable to cholesterol testing. He believes this innovation illustrates a new era in Alzheimer's research, where advancements in science and technology are leading to more accessible and effective diagnostic tools.
Scientists developing new diagnostic tool that can deliver health test results in two minutes
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hindustan Times
44 minutes ago
- Hindustan Times
Engineering humanity & where to draw a line
The future of human reproduction and genetic design is accelerating faster than most people understand, driven not by national debates or international accords, but by software startups, biotech investors, and quiet breakthroughs in fertility clinics. Nucleus Genomics recently unveiled Nucleus Embryo, a genetic screening platform that allows prospective parents to assess up to 20 embryos for more than 900 conditions and traits. These include not only polygenic risk scores for diseases such as cancer and Alzheimer's but also traits such as intelligence, height, and anxiety. In short, it offers a pathway to genetic optimisation — allowing parents to select not only healthier babies but the human features they want. Orchid, another US startup, pioneered full-genome sequencing of IVF embryos for disease screening. Once exclusive to the ultra-wealthy, Orchid's services are rapidly becoming more affordable, pointing to a future where embryo selection could become a standard step in family planning for both the middle and upper class. Meanwhile, Coinbase CEO Brian Armstrong, known for backing radical biotech ventures, has announced plans to launch a US company that would go beyond selection into embryo editing. Thanks to recent advances in base editing, it is now possible to alter individual DNA letters with high precision rewriting, rather than merely reading the code of life. The commercial race toward Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) babies has begun — and this is something I have long been both excited and terrified about. In a 2017 Washington Post article, I asked: 'Human editing has just become possible. Are we ready for the consequences?' I warned that CRISPR had made embryo editing technically feasible, but that society wasn't prepared for the moral fallout. I feared we would drift from preventing disease to designing our children. We have crossed this Rubicon. While the global community debates ethics and oversight, China is racing ahead with few restraints. Chinese scientists are editing the genes of animals — and even human embryos — not only to treat disease but to enhance traits such as intelligence and strength. Their goal appears to be the creation of so-called superhumans. Without international standards and ethical guardrails, unchecked ambition in any one country can pose risks for all of humanity. India must pay close attention. It has already misused reproductive technology: Ultrasound machines meant for foetal health monitoring were widely repurposed for sex selection. In Haryana, the sex ratio at birth has declined to 910 girls for every 1,000 boys. In a society shaped by caste, colourism, and academic pressure, gene editing could easily be co-opted to entrench inequality under the banner of 'better futures'. But more than vigilance, India must lead. With a deep-rooted traditions of spiritualism, karma and ethics, and respect for human dignity, it is uniquely positioned to offer the moral leadership this moment demands. Its scientific community is world-class, and its track record — from generic medicine to vaccine equity — shows it can pair innovation with compassion. The concerns extend far beyond reproduction. Gene-edited crops could marginalise small farmers if patented seeds are controlled by large corporations. CRISPR-based therapies, already costing more than $500,000 in the West, could deepen biological inequality. Even gene drives, designed to eliminate diseases such as malaria, could threaten delicate ecosystems like the Sundarbans if not deployed with care. To lead responsibly, India must act on four fronts. First, accelerate research. Universities and public institutions should partner with socially responsible entrepreneurs to build local expertise in gene editing, synthetic biology, and bioethics. This collaboration can ensure innovation is aligned with the public interest and rooted in Indian values rather than imported priorities. Second, access must be equitable. India has done this before with lifesaving generic drugs and can do this again. Public funding and subsidies must ensure CRISPR therapies reach rural and tribal populations suffering from genetic disorders like thalassemia. Third, the entire regulatory framework needs to be updated because existing biotech laws predate CRISPR. A new structure, co-created with scientists, ethicists, civil society, and patients, must define what is allowed, what is off-limits, and how oversight will function. Real engagement with the public, not just top-down mandates, will be essential. Fourth, India must lead globally. As it did in championing affordable vaccines, it can help shape international norms for genetic science, banning non-medical trait selection, regulating gene drives, and insisting on transparency and accountability. India can set the ethical benchmark, not merely follow it. We now have a rare opportunity to prove that scientific progress and moral clarity can coexist, but the window is narrow. We cannot rely on Silicon Valley, where profit is the only true metric of success, nor on China, where State control and repression define scientific ambition. Both paths risk taking humanity into dangerous territory. The world needs a third way, rooted in spiritual values, ethical reasoning, and the belief that technology must serve the many, not just the powerful, and this is the role India must play. Vivek Wadhwa is CEO, Vionix Biosciences. The views expressed are personal.
Hindustan Times
6 hours ago
- Hindustan Times
The many benefits of rosemary: Secret to brain health is hiding in your kitchen
Rosemary, the aromatic herb native to the Mediterranean, has long been a staple in kitchens around the world. However, a recent study led by Dipa Kamdar from Kingston University reveals that rosemary's benefits go far beyond its culinary appeal. This powerful herb plays a vital role in supporting brain health, reducing inflammation, and enhancing immune function. Also read | Looking for hair growth solution? Try rosemary oil; doctor reveals this simple herb oil is the go-to for thicker hair According to multiple studies, rosemary has been associated with healthy brain function. One study associated rosemary to decreased risk of Alzheimer's. According to a study conducted by the researchers at Northumbria University, participants who inhaled rosemary's scent performed better in memory tasks than the ones who performed the same tasks in an unscented environment. Even historically, rosemary had been associated with better brain functioning. It is believed that in ancient Greece and Rome, students used rosemary to improve concentration and memory. Also read | Super herb: Benefits of rosemary water for great hair Blood circulation: Rosemary helps in stimulating blood circulation in the brain, which helps in delivering more blood and nutrients that can improve mental clarity. Calming properties: The aroma of rosemary is believed to have calming properties that can help in reducing anxiety and stress. It also helps in inducing better sleep. Lower stress can help in better memory retention and clarity. Antioxidants: Oxidative stress can cause damage to brain cells, that can affe4ct cognitive functioning. Rosemary is packed with antioxidants that can prevent this process. Also read | Habits that damage your brain health: Modern lifestyle routines you need to stop immediately Health-enhancing effects: Rosemary is loaded with carnosic acid, an antioxidant and an anti-inflammatory agent that helps in shielding brain cells from harm. Beyond brain health: rosemary's health effects go beyond the brain. It also helps in easing digestion, relieving bloating and reducing inflammation. Note to readers: This article is for informational purposes only and not a substitute for professional medical advice. Always seek the advice of your doctor with any questions about a medical condition.
Mint
6 hours ago
- Mint
Chinese Firm Halts Production of Controversial Alzheimer's Drug
(Bloomberg) -- A Chinese company that developed the country's first indigenous therapy for Alzheimer's disease has suspended production and sales of the drug, casting doubts on the treatment's future. The drug's license has expired and its renewal is now in the final stages of a regulatory review, during which it must stop commercial production and sales, Green Valley Pharmaceutical Co. said in an emailed statement to Bloomberg News on Tuesday. The Shanghai-based drugmaker informed employees of the production halt in an internal notice at the end of May, local media Yicai reported first on Monday. Green Valley's drug — a seaweed-derived compound known as sodium oligomannate, or GV-971 — was hailed as a major advance when China's drug regulator gave it conditional approval in 2019, as the first new therapy endorsed for Alzheimer's in 17 years. Local and international medical experts have since questioned how effective it really is in slowing or reversing the cognitive declines of Alzheimer's patients given the relatively short duration of — and the inconsistent results shown in — its late-stage clinical trial in China. The company launched a global clinical trial in 2020, seeking to enroll some 2,000 patients across China, the US and Europe. It was terminated two years later due to a lack of funding and Covid pandemic disruptions. Green Valley previously conducted post-marketing clinical studies on around 3,300 patients on sodium oligomannate in China and has planned to present the results at an international academic conference later this year, according to the company. The changes are temporary and limited to operations related to sodium oligomannate, the company said, adding that drug supply for clinical trials is unaffected. 'We are in close communications with relevant authorities and believe patients' treatment needs will be met soon,' it said in the email. The closely-held company has not disclosed sales revenue for GV-971 in China, where it was included for national insurance reimbursement in 2022 at a price of around $41 per box. Hospital and retail sales of GV-971 topped $45.4 million (326 million yuan) that year, Yicai reported, citing figures from Pharnexcloud — a database of national hospital sales in China. China has since approved two new Alzheimer's therapies developed by multinational drugmakers: Biogen Inc. and Eisai Co.'s Leqembi, and Kisunla from Eli Lilly & Co. The country has 17 million dementia patients — about 30% of the global total — per a 2024 report led by Shanghai Jiao Tong University School of Medicine. More stories like this are available on
